Biofrontera, Inc. (BFRI)
| Market Cap | 28.03M |
| Revenue (ttm) | 27.71M |
| Net Income (ttm) | -25.81M |
| Shares Out | 23.55M |
| EPS (ttm) | -2.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 730,536 |
| Open | 1.19 |
| Previous Close | 1.15 |
| Day's Range | 1.15 - 1.22 |
| 52-Week Range | 1.14 - 14.63 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 15.81 (+1,228.6%) |
| Earnings Date | Aug 12, 2022 |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impe... [Read more...]
Financial Performance
In 2021, Biofrontera's revenue was $24.10 million, an increase of 27.86% compared to the previous year's $18.85 million. Losses were -$37.71 million, 243.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BFRI stock is "Buy." The 12-month stock price forecast is 15.81, which is an increase of 1,228.57% from the latest price.
News
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduc ed Pain Intensity while Maintaining Efficacy
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has ent...
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
Named A mong the 10 Fastest - Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Co...
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's ...
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin canc...
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closin...
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial resul...
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser E...
Live Demonstration of New RhodoLED ® XL to be Featured
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
Ameluz® for the treatment of actinic keratoses now at www.ameluz.com Xepi® for the treatment of impetigo now at www.xepicream.com
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
Significantly Improves Manufacturing Efficiency , Quality Control and Supply Reliability
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday
We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stock...
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
I ntroduces 2022 financial guidance Conference call begins at 11 :0 0 a .m. Eastern time today
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today prelimina...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will r...
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual ...
Company to have a strong onsite presence at the world's l argest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-...
WOBURN, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI ) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that th...
Biofrontera Inc. to Present at the 34th Annual Roth Conference
WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces...
Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces...
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased...
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for...
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issu...
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today anno...
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced ...
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the...